Clinical trials: Advanced Solid Malignancy
Malignant Melanoma, Medullary Thyroid Cancer
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
- Conditions
- Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma
- Trial name
- NCT02709889
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 30 sites in United States
- Volunteers
- 200 people
- Sponsor
- AbbVie
Advanced Solid Tumors
A Study of Talazoparib in Patients With Advanced Solid Tumors
This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.
- Trial name
- NCT03070548
- Testing
- Talazoparib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Lymphoma
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and…
- Trial name
- NCT01714947
- Testing
- [^14C]-alisertib, alisertib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor, Kidney Cancer
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
This research study is evaluating the combination of pazopanib and everolimus in patients that have a malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no…
- Trial name
- NCT01184326
- Testing
- pazopanib, everolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumors
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
This study will investigate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) activity of adavosertib, both as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in participants with…
- Trial name
- NCT00648648
- Testing
- adavosertib, gemcitabine, cisplatin
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
- Trial name
- NCT02997176
- Testing
- Talazoparib
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pfizer
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Metastatic Solid Tumors
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
- Trial name
- NTRK (NCT04010240)
- Testing
- No intervention (this is a retrospective cohort study)
- Where
- France
- Volunteers
- 3,820 people
- Sponsor
- Institut Bergonié
Neoplasms
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
A dose escalation study to determine the safety and maximum tolerated dose (MTD) of IMC-3C5 in subjects with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available.
- Trial name
- NCT01288989
- Testing
- IMC-3C5
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Lymphoma
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
The purpose of this study is to identify a maximum tolerated dose (MTD) or maximum administered dose (MAD) of ulevostinag alone and of ulevostinag in combination with pembrolizumab in participants with advanced/metastatic solid…
- Trial name
- NCT03010176
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose…
- Trial name
- MINOTAUR (NCT05147350)
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 38 people
- Sponsor
- Debiopharm International SA
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Solid Tumours
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation…
- Trial name
- NCT01928940
- Testing
- dabrafenib, trametinib
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Unspecified Adult Solid Tumor, Protocol Specific
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00607724
- Testing
- GDC-0449
- Volunteers
- 68 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab…
- Trial name
- NCT02671435
- Testing
- Monalizumab, Durvalumab, Cetuximab
- Where
- 49 sites in United States, Australia and 9 more
- Volunteers
- 383 people
- Sponsor
- MedImmune LLC
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Ovarian, Breast
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
- Conditions
- Ovarian, Breast, Prostate, Pancreatic
- Trial name
- NCT01078662
- Testing
- olaparib
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 298 people
- Sponsor
- AstraZeneca
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439123
- Testing
- Capivasertib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response.
- Trial name
- VA (NCT00748553)
- Testing
- Azacitidine (Vidaza), Nab-paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah